No recent analyst price targets found for AVCT.
Latest News for AVCT
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVCT.
U.S. House Trading
No House trades found for AVCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.